AstraZeneca's LATIFY Phase III Trial of Ceralasertib Plus Imfinzi Fails to Meet Primary Endpoint in Advanced Lung Cancer
核心洞察
AstraZeneca's Phase III LATIFY trial evaluating ceralasertib combined with Imfinzi failed to meet its primary endpoint of overall survival versus docetaxel in patients with advanced non-small cell lung cancer (搜索).
The trial enrolled 594 patients across more than 20 countries with locally advanced or metastatic NSCLC without actionable genomic alterations whose disease progressed after prior immunotherapy and platinum-based chemotherapy.
Despite the efficacy disappointment, the combination of ceralasertib and Imfinzi was generally well tolerated with a safety profile consistent with known profiles of each individual medicine.
AstraZeneca announced that its Phase III LATIFY clinical trial evaluating ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (搜索) (NSCLC). The trial specifically evaluated patients without actionable genomic alterations whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.
Trial Design and Patient Population
The LATIFY trial was a randomised, open-label, multi-centre, global Phase III study that enrolled 594 patients across more than 20 countries. Patients were randomised 1:1 to receive either ceralasertib 240mg twice daily oral tablets for seven days in combination with a 1,500mg fixed dose of Imfinzi on day eight every four weeks, or docetaxel every three weeks until disease progression, unacceptable toxicity, withdrawal of consent or a discontinuation criterion was met.
The primary endpoint was overall survival, with secondary endpoints including progression-free survival, objective response rate, duration of response, time to response, disease control rate and patient reported outcomes.
Treatment Rationale and Mechanism
Ceralasertib is an oral, potent and selective inhibitor of the ATR kinase, which is crucial for DNA damage responses and cell survival. The drug acts on the tumour microenvironment, moving it from a suppressed immune state into an activated state when combined with immunotherapy. Imfinzi is a human monoclonal antibody that binds to the PD-L1 (搜索) protein and blocks the interaction of PD-L1 with the PD-1 (搜索) and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer (搜索) whose tumours stopped responding to available therapies by combining ATR inhibition with immunotherapy," said Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca. "While we are disappointed by this result, we remain committed to pioneering new medicines to address the urgent need to improve outcomes for patients with lung cancer through our industry-leading portfolio."
Safety Profile
Despite the efficacy disappointment, the combination of ceralasertib and Imfinzi was generally well tolerated, and the safety profile was consistent with the known profiles of each individual medicine, with no new safety concerns identified. These data will be presented at a forthcoming medical meeting.
Clinical Context
Lung cancer (搜索) is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths. NSCLC accounts for about 80-85% of lung cancer cases, with patients most commonly diagnosed with metastatic disease when the tumour has spread outside the lung. Approximately 12% of people with metastatic NSCLC will still be alive five years after diagnosis.
The outcome of the LATIFY Phase III trial highlights the challenges of developing new combination therapies in oncology, particularly in highly competitive areas such as lung cancer (搜索) treatment. The results represent a setback for AstraZeneca's approach to combining ATR inhibition with immunotherapy in this patient population, though the company continues to invest heavily in oncology research with a broad pipeline focused on innovative cancer therapies.